The Middle East & Africa Alopecia Market was worth USD 0.50 billion in 2023 and is estimated to be growing at a CAGR of 7.06%, to reach USD 0.70 billion by 2028.
Alopecia is a medical condition that refers to sudden, excessive hair loss on the head area, mostly in circular patches. One such type of alopecia - Alopecia areata is a common autoimmune disease that causes baldness that results in partial or complete hair loss.
An increase in the prevalence of alopecia which is due to constant changes in the environment with the lack of Vitamin D is also the most common cause of hair loss due to the hereditary condition among people which happens with aging. Since Dubai has the highest cases of hair loss among other countries, which is due to the climatic changes that are dry and dull, which makes the hair dehydrated and causes hair loss. Therefore, the increase in the demand and need for hair treatment is driving the growth of MEA alopecia treatment market.
The increase in the development and advancement in the technology for effective treatments and modifying various types of hair products, and coming up with new treatments are propelling the market growth of the Middle East & Africa alopecia treatment market. Also, initiatives and investments from government and non-government in the research processes for developing new drugs for the treatment of hair loss promote the growth of the MEA alopecia market.
Furthermore, the growing awareness about the increasing prevalence of alopecia and the treatment available in the market, the growth in the population, and the rising concerns from both men and women towards hair loss.
Moreover, growing competition between the market players with is various types of products enhances the alopecia market's growth by introducing different types of hair care products with other medications present in the market.
However, side effects related to the alopecia treatment and can cause other diseases such as autoimmune diseases like thyroid disease, rheumatoid arthritis, are limiting the growth of the MEA alopecia market. As well as increased substitute products and treatments available in the market are affecting the growth of the Middle East & Africa Alopecia market.
This research report on the MEA alopecia market has been segmented and sub-segmented into the following categories:
By Disease Type:
By Sales Channel:
By End Use:
The MEA alopecia market is expected to account for a considerable share which is fuelled by the proliferation of alopecia with the increase in the population with the rise in the geriatric population as well as due to increasing in the approval process for the introduction of the product in the market.
UAE is dominating the market due to increase in hair loss cases as it has the highest hair loss cases in the region, which is due to the presence of climatic conditions which causes hair loss among the people as well as with the advanced hair studio for the treatment of hair loss is accelerating the market growth.
Saudi Arabia and South Africa are estimated to see major growth in the market during the forecast period. The market growth is expected to be driven by the increase in the government and non-government in the research processes for the development of products. Also, growing awareness of the innovative products and the concerns related to hair loss is fuelling the market growth of the Middle East & Africa alopecia market.
KEY MARKET PLAYERS:
Johnson & Johnson, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd and Zhangguang 101 Science & Technology Co., Ltd are a few of the noteworthy companies in the MEA alopecia treatment market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]